EP1904514A2 - Formes cristallines de ciclesonide - Google Patents

Formes cristallines de ciclesonide

Info

Publication number
EP1904514A2
EP1904514A2 EP07763367A EP07763367A EP1904514A2 EP 1904514 A2 EP1904514 A2 EP 1904514A2 EP 07763367 A EP07763367 A EP 07763367A EP 07763367 A EP07763367 A EP 07763367A EP 1904514 A2 EP1904514 A2 EP 1904514A2
Authority
EP
European Patent Office
Prior art keywords
ciclesonide
crystalline form
theta
degrees
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07763367A
Other languages
German (de)
English (en)
Inventor
Rossetto Pierluigi
Peter Lindsay Macdonald
Sigalit Levi
Judith Aronhime
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sicor Inc
Original Assignee
Sicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Inc filed Critical Sicor Inc
Publication of EP1904514A2 publication Critical patent/EP1904514A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention encompasses a new crystalline form of ciclesonide and methods for the preparation thereof.
  • the invention also encompasses pharmaceutical compositions comprising the new crystalline form of ciclesonide and to processes for preparation thereof.
  • Ciclesonide is an ester prodrug essentially devoid of oral bioavailability, which is activated upon cleavage by endogenous esterases.
  • Polymorphism the occurrence of different crystal forms, is a property of some molecules and molecular complexes.
  • a single molecule like ciclesonide, may give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, x-ray diffraction pattern, infrared absorption fingerprint, and solid state NMR spectrum.
  • One crystalline form may give rise to thermal behavior different from that of another crystalline form. Thermal behavior can be measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (“TGA”), and differential scanning calorimetry (“DSC”), which have been used to characterize crystal forms.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • polymorphs are distinct crystalline forms sharing the same molecular formula yet having distinct advantageous physical properties as compared to other crystalline forms of the same compound or complex.
  • aqueous solution particularly their solubility in the gastric juices of a patient.
  • solubility in the gastric juices of a patient.
  • absorption through the gastrointestinal tract is slow, it is often desirable for a drug to dissolve slowly so that it does not accumulate in a deleterious environment. This is particularly true when the drug is unstable to conditions in the patient's stomach or intestine.
  • Different crystalline forms or polymorphs of the same pharmaceutical compound can (and reportedly do) have different aqueous solubility.
  • crystal structure as well as crystal shape (morphology) and size has a significant practical and commercial impact on active substances, especially on formulations for inhalation.
  • the ideal particles for inhalation delivery are spherical of low density and small in size having a narrow size distribution.
  • size can be controlled by direct crystallization or by micronization. The micronization process may lead to partial crystal form transformation or, in some cases, to the production of amorphous areas. These amorphous areas are more reactive and increase the instability of the active substances because the areas can recrystallize and cause particle bridging.
  • Particle bridging in turn can increase the particle size.
  • the discovery of new polymorphic forms of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical formulation. It also enlarges the repertoire of materials that a formulation scientist has available for designing a pharmaceutical dosage form of a drug such as a targeted release profile or other desired characteristic. Because of limited options, there is a need in the art for novel polymorphic forms of ciclesonide, such as those present below.
  • One embodiment of the invention encompasses a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta ⁇ 0.2 degrees two-theta.
  • Another embodiment of the invention encompasses a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta, and at least one pharmaceutically acceptable excipient.
  • Yet another embodiment of the invention encompasses a process for preparing pharmaceutical compositions of a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta, comprising mixing a therapeutically, effective amount of a crystalline form of ciclesonide characterized by. an XRD pattern having peaks at about 11.0, 14.8,
  • One embodiment of the invention encompasses the use of a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta ⁇ 0.2 degrees two-theta for the manufacture of a pharmaceutical composition.
  • the patent or application file contains at least one drawing executed in color.
  • Figure 1 illustrates a powder X-ray diffraction pattern of the crystalline form of ciclesonide obtained by repeating Example 1 of EP patent No. 929566.
  • Figure 2 illustrates a powder X-ray diffraction pattern of the crystalline form of ciclesonide of the invention.
  • Figure 3 illustrates a photomicrograph of the crystalline form of ciclesonide obtained by repeating Example 1 of EP patent No. 929566.
  • Figure 4 illustrates a photomicrograph of the crystalline form of ciclesonide of the invention. Detailed Description of the Invention
  • the invention encompasses a new crystalline form of ciclesonide, which is a solvated form of ciclesonide. Purification of ciclesonide via the solvated form providing substantially pure ciclesonide.
  • the invention encompasses a novel crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two- theta ⁇ 0.2 degrees two-theta.
  • the crystalline form may be further characterized XRD pattern having peaks at about 5.6, 18.3, 19.5, 20.7 and 22.0 degrees two-theta, ⁇ 0.2 degrees two-theta.
  • the crystalline form may also be characterized by an XRD pattern substantially depicted in Figure 2.
  • the crystalline form may also be characterized by a weight loss of about 10% by weight, as measured at a temperature from about 25°C to about 130 0 C using thermal gravimetric analysis ("TGA").
  • the crystalline form of ciclesonide of the invention may be further characterized by a melting temperature of about 207 0 C.
  • the crystalline form may be a solvate.
  • the crystalline form is a solvate of tert-butanol in a ratio of 1:1 cicleso ⁇ idertert-butanol (about 12% tert-butanol by weight).
  • the crystalline form can be characterized by any other method known to a skilled artisan, such as solid state NMR and FTIR.
  • the above crystalline form of ciclesonide exists in a morphology of spherical and irregular shape.
  • the term "irregular" refers to a crystal that has a morphology which is not spherical or plate shape.
  • the crystalline form may also be substantially identified by a photomicrograph depicted in Figure 4. This photomicrograph shows that some of the crystals have a spherical shape morphology and some have an irregular morphology.
  • the crystalline form of ciclesonide can have morphology suitable for inhalation delivery.
  • the invention encompasses a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta, and having no more than about 5% by weight of other forms of ciclesonide as determined by XRD.
  • the crystalline ciclesonide has no more than 2% by weight of other forms of ciclesonide as determined by XRD.
  • the above form of ciclesonide has not more than about 5% by weight of the crystalline form of ciclesonide characterized by a PXRD pattern having peaks at 7.0, 15.0, 17.0, 17.5, and 18.4 degrees two-theta and additional peaks at 5.6, 12.7, 14.5, 19.3, and 20.2 degrees two-theta.
  • the above form of ciclesonide has not more than about 2% by weight of the crystalline form of ciclesonide characterized by a PXRD pattern having peaks at 7.0, 15.0, 17.0, 17.5, and 18.4 degrees two-theta and additional peaks at 5.6, 12.7, 14.5, 19.3, and 20.2 degrees two-theta.
  • the invention encompasses a process for the preparation of the crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta, comprising crystallization from t-butanol.
  • the process for making a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta comprises dissolving ciclesonide in tert-butanol at a temperature of about 50 0 C to about 70 0 C to form a solution, cooling the solution to a temperature of about 25 0 C to about 35°C to induce ciclesonide crystallization, and isolating crystalline ciclesonide.
  • the ciclesonide used as the starting material may be made by the methods described in the prior art, such as PCT publication Nos. WO 98/09982 and WO 2004/085460, and U.S. Patent No. 5,482,934, hereby incorporated by reference.
  • the ciclesonide has a purity of at least 99%'area by HPLC.
  • the ciclesonide can be obtained by crystallization from a ⁇ on-hydroxylic organic solvent selected from a group consisting OfC 6 - S linear or branched aliphatic hydrocarbon, C 2 - 5 ether, and mixtures thereof, as described in U.S. Application Serial No. 11/592,475, filed on November 2, 2006 and hereby incorporated by reference.
  • One method for making the starting ciclesonide for the invention encompasses crystallizing ciclesonide from a water-immiscible organic solvent. This process comprises dissolving ciclesonide in at least one water-immiscible organic solvent to form a solution; crystallizing ciclesonide from the solution; and recovering the crystallized ciclesonide.
  • the water-immiscible organic solvent is a non- hydroxylic organic solvent.
  • the starting ciclesonide can be made using methods known in the art, such as the methods disclosed in U.S. Patent Nos. 2,990,401 ; 3,929,768; 4,695,625, 4,925,933; 5,482,934; and 5,728,826, and disclosed in PCT publications WO 98/09982 and WO 2004/085460, hereby incorporated by reference.
  • the starting ciclesonide contains no more than about 15% of the 22S-epimer as determined by HPLC. More preferably, the starting ciclesonide contains no more than about 12% of the 22S-epimer as determined by HPLC.
  • Water-immiscible organic solvents include non-hydroxylic organic solvent.
  • the non-hydroxylic organic solvents are organic solvents that lack a hydroxyl group in the chemical compound.
  • the non-hydroxylic organic solvent includes Ci-Ci 2 straight, branched or cyclic alkanes and C 2 to Ci 2 straight, branched or cyclic ethers.
  • the Ci-Cn straight, branched or cyclic alkanes are Ce-Cn straight, branched or cyclic alkanes. and more preferably, C 6 -Cs straight, branched or cyclic alkanes.
  • the C 2 to Ci 2 straight, branched or cyclic ethers are C5 to Ci 2 straight, branched or cyclic ethers, and more preferably, C 5 to Ce straight, branched or cyclic ethers.
  • Specific examples of Ci -Ci 2 straight, branched or cyclic alkanes include heptane, hexane, and isooctane.
  • Specific examples of C 2 to C] 2 straight, branched or cyclic ethers include tert- butyl methyl ether, and diisopropyl ether.
  • the non-hydroxylic organic solvent is isooctane.
  • the crystallization process may further employ a second organic solvent, wherein the term second organic solvent refers to an organic solvent that has a boiling point lower than the non-rhydroxylic organic solvent.
  • The. lower-boiling organic solvent can be any solvent that can dissolve the starting mixture of ciclesonide 22R/22S epimers.
  • the lower-boiling organic solvent includes Ci to Cs alcohols, C 2 to C 8 ketones, and Cue aliphatic halocarbons.
  • the Ci to C 8 alcohols is Ci to C 5 alcohols, and more preferably, Ci to C 4 alcohols.
  • the C2 to C 8 ketones are C 2 to C 5 ketones, and more preferably, C 2 to C 3 ketones.
  • the Ci- ⁇ aliphatic halocarbons are Ci ⁇ aliphatic halocarbons, and more preferably, Cu 2 aliphatic halocarbons.
  • Specific examples of Ci to C 8 alcohols include methanol, ethanol, and tert-butanol.
  • Specific examples of C 2 to Cs ketones include acetone.
  • Specific examples of Ci -6 aliphatic halocarbons include dichloromethane. More preferably, the lower-boiling organic solvent is either acetone or dichloromethane, and most preferably, dichloromethane.
  • the co-solvent is preferably technical grade, i.e.
  • the ratio of the solvents is 20:1 by weight, respectively.
  • the ratio is 10:1, and more preferably, the ratio is 5:1 by weight.
  • the lower-boiling organic solvent may be removed by evaporation prior to inducing precipitation of the crystalline ciclesonide.
  • the crystallization is performed by dissolving the starting ciclesonide in the water-immiscible organic solvent at a temperature ranging from ambient temperature to about the boiling point of the water-immiscible organic solvent to form a solution, concentrating the solution to obtain a suspension, and cooling the suspension to precipitation of solid ciclesonide.
  • the process preferably comprises dissolving the starting ciclesonide in the second lower-boiling organic solvent at a temperature ranging from ambient temperature to the boiling point of the second lower-boiling organic solvent, and adding the water- immiscible organic solvent. The mixture may then be concentrated to remove most or all of the second lower-boiling organic solvent, which removal typically results in a suspension.
  • the suspension obtained either with or without the second solvent is cooled to a temperature of about 80 0 C to about 10 0 C.
  • the concentrating step is performed by removing the water-immiscible organic solvent by distillation.
  • the precipitate may be separated or recovered using methods commonly known to the skilled artisan.
  • the crystalline ciclesonide may be recovered by filtration.
  • the recovered crystalline ciclesonide is washed and dried.
  • the temperature for dissolving ciciesom ⁇ e should be sufficient to dissolve ciclesonide in tert-butanol.
  • the temperature for dissolving ciclesonide in tert-butanol is about 55°C to about 65 0 C, and more preferably, the temperature is about 60 0 C.
  • the cooling temperature should be lower than the dissolving temperature and sufficient to induce the crystallization of ciclesonide.
  • the solution is cooled at a temperature of about 30 0 C to about 25°C, and more preferably, the temperature is about 27°C to about 26°C.
  • the solution can be stirred during the cooling step.
  • the crystalline form of ciclesonide may be isolated by filtration of the precipitate. Filtration can be carried out by methods including, but not limited to, suction followed by washing of the precipitate.
  • the precipitate can be washed with 2,2,4-trimethylpentane and subsequently dried for about 8 hours in a vacuum oven.
  • the vacuum is about 5 to 10 mm Hg.
  • the drying step is carried out at a temperature of about 80 0 C.
  • the crystalline form of ciclesonide obtained by the crystallization process described above typically contains no more than about 5% by weight of other crystalline forms of ciclesonide as determined by XRD.
  • the crystalline form of ciclesonide has no more than 2% by weight of other crystalline forms of ciclesonide as determined by XRD.
  • the invention also encompasses a process of increasing the R/S epimeric ratio of ciclesonide comprising dissolving ciclesonide having a first R/S epimeric ratio with a sufficient amount of acetone to form a solution and heating the solution to reflux; adding isooctane to the heated solution and heating the solution to about 90 0 C; cooling the suspension to about 70 0 C for about 30 minutes; allowing the solution to cool to about 25°C to about 28°C; then to and collecting the crystalline ciclesonide, wherein the crystalline ciclesonide has a second R/S epimeric ratio and the second R/S epimeric ratio is greater than the first R/S epimeric ratio.
  • the process further comprises drying the collected crystalline ciclesonide at a temperature of about 80 0 C under vacuum.
  • the ratio of acetone to isooctane is about 1 :l-40 by volume.
  • the ratio of acetone to isooctane is about 1:2-30 by volume, and more preferably, the ratio of acetone to isooctane is about 1 :5-20 by volume.
  • the second R/S epimeric ratio is about 96.5:3.5, preferably about 98:2, and more preferably, 99:1, and most preferably about 99.75:0.25 as determined by HPLC area.
  • the invention also encompasses pharmaceutical compositions comprising a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta, and at least one pharmaceutically acceptable excipient.
  • the invention also encompasses processes for the preparation of pharmaceutical compositions of a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta, comprising mixing a therapeutically effective amount of a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta with at least one pharmaceutically acceptable excipient.
  • the term "therapeutically effective amount” refers to an amount of ciclesonide sufficient to achieve the desired biological : effect.
  • the amount of ciclesonide is sufficient to act as a bronchodilator when administered to a patient suffering from a respiratory disease, such as asthma.
  • the amount will depend upon the method of use, the age, sex, and condition of the patient, which a skilled artisan can easily determine with little or no experimentation.
  • the amount of the crystalline form of ciclesonide in a pharmaceutical composition for treating atherosclerosis or hypercholesterolemia should be sufficient to treat or ameliorate atherosclerosis or hypercholesterolemia.
  • the invention also encompasses the use of a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta, for the manufacture of a pharmaceutical composition comprising the same.
  • compositions comprising a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta, may be prepared by combining the crystalline form with at least one diluent or excipient, wherein the diluent or excipient includes, but is not limited to, carriers, fillers, bulking agents, binders, wetting agents, disintegrating agents, disintegration inhibitors, absorption accelerators, adsorbing agents, surface active agents, or lubricants.
  • the pharmaceutical composition of the invention should maintain the novel crystalline form of ciclesonide (no solution formulations); however, methods of making pharmaceutical compositions of the invention may include solutions.
  • compositions may be shaped into various modes for the administration of the pharmaceutical compositions including, but not limited to, tablets, pills, powders, suspensions, emulsions, granules, capsules, suppositories, or injection preparations.
  • Carriers used include, but are not limited to, lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, and the like.
  • Binders used include, but are not limited to, water, ethanol, propanol, simple syrup, glucose solutions, starch solutions, gelatin solutions, carboxymethyl cellulose, shelac, methyl cellulose, potassium. phosphate, ; . . ., .. polyvinylpyrrolidone, and the like.
  • Disintegrating agents used include, but are not limited to, dried starch, sodium alginate, agar powder, laminalia powder, sodium hydrogen carbonate, calcium carbonate, fatty acid esters of polyoxyethylene sorbitan, sodium laurylsulfate, monoglyceride of stearic acid, starch, lactose, and the like.
  • Disintegration inhibitors used include, but are not limited to, white sugar, stearin, coconut butter, hydrogenated oils, and the like.
  • Absorption accelerators used include, but are not limited to, quaternary ammonium base, sodium laurylsulfate, and the like.
  • Wetting agents used include, but are not limited to, glycerin, starch, and the like.
  • Adsorbing agents used include, but are not limited to, starch, lactose, kaolin, bentonite, colloidal silicic acid, and the like.
  • Lubricants used include, but are not limited to, purified talc, stearates, boric acid powder, polyethylene glycol, and the like.
  • tablets can be coated with commonly known coating materials such as those coatings used in sugar coated tablets, gelatin film coated tablets, tablets coated with enteric coatings, tablets coated with films, double layered tablets, and multi-layered tablets.
  • any commonly known excipient used in the art to make pills can be used.
  • pills carriers include, but are not limited to, lactose, starch, coconut butter, hardened vegetable oils, kaolin, talc, and the like.
  • binders used include, but are not limited to, gum arabic powder, tragacanth gum powder, gelatin, ethanol, and the like.
  • Disintegrating agents used include, but are not limited to, agar, lan ⁇ inalia, or the like.
  • any commonly known excipient used in the art can be used.
  • the excipients used in suppositories include, but are not limited to, polyethylene glycols, coconut butter, higher alcohols, esters of higher alcohols, gelatin, or semisynthesized glycerides.
  • injectable pharmaceutical compositions When preparing injectable pharmaceutical compositions, solutions and suspensions are sterilized and are preferably made isotonic to blood. Injection preparations may use carriers commonly known in the art, including, but not limited to, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, or fatty acid esters of polyoxyethylene sorbitan.
  • carriers commonly known in the art including, but not limited to, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, or fatty acid esters of polyoxyethylene sorbitan.
  • compositions of the invention may be administered in a variety of methods depending on the age, sex, and symptoms of the patient. For example, tablets, pills, solutions, suspensions, emulsions, granules and capsules may be orally administered.
  • Injection preparations may be administered individually or mixed with injection transfusions such as glucose solutions and amino acid solutions intravenously- If necessary, the injection preparations may be administered intramuscularly, intracutaneously, subcutaneously or intraperitoneally. Suppositories may be administered into the rectum.
  • X-Ray powder diffraction data was obtained by using method known in the art using a SCINTAG powder X-Ray diffractometer model X'TRA equipped with a solid- state detector. Copper radiation of 1.5418 A was used. A round aluminum sample holder with zero background was used. The scanning parameters included: range: 2-40 degrees two-theta; scan mode: continuous scan; step size: 0.05 deg.; and a rate of 5 deg/min. All peak positions are within ⁇ 0.2 degrees two theta.
  • Ciclesonide (>99% by HPLC) was dissolved in 3.37 parts of absolute ethanol at reflux; and 1.96 parts of water were added to the boiling mixture. The mixture was then allowed to cool to RT with vigorous stirring, and the precipitate was filtered off with suction, washed with 1.58 parts of absolute ethanol /water (2/1 v/v) and dried for 5 h at 50 0 C under vacuum, to obtain a crystalline ciclesonide.
  • the crystalline material was analyzed by PXRD showing a pattern having peaks at about 7.0, 15.0, 17.0, 17.5 and 18.4 degrees two-theta ⁇ 0.2 degrees two-theta, and additional peaks at 5.6, 12.7, 14.5, 19.3 and 20.2 degrees two-theta ⁇ 0.2 degrees two-theta.
  • Example 2 Preparation of the crystalline form of ciclesonide characterized by a PXRD pattern having peaks at about 11.0. 14.8. 15.7, 16.5, and 22.8 degrees two-theta. ⁇ 0.2 degrees two-theta
  • Ciclesonide (>99% by HPLC) was dissolved at 70 0 C in 6.25 parts of tert-butanol and 10.0 parts of water. The solvent was distilled off with vacuum, and 5.0 parts of water were added. The mixture was allowed to cool to R.T. under vigorous stirring, and the precipitate was filtered off with suction, and washed with 5.0 parts of water.
  • Example 3 Preparation of the crystalline form of ciclesonide characterized by a PXRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, db 0.2 degrees two-theta
  • Ciclesonide (>99% by HPLC) was dissolved in 3.0 parts w/w of tert-butanol at 60°C. The solution was allowed to cool to 26°C to 27°C under stirring, and the precipitate was filtered off with suction, washed with 2.0 parts w/w of 2,2,4-trimethylpentane and dried for 8 h at 80 0 C under vacuum. The melting point was 206.9 0 C.
  • the dried precipitate was analyzed by XRD showing a crystalline ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta, ⁇ 0.2 degrees two-theta and having no more than 5% by weight of crystalline form of ciclesonide having XRD showing a pattern having peaks at about 7.0, 15.0, 17.0, 17.5 and 18.4 degrees two-theta ⁇ 0.2 degrees two-theta, and additional peaks at 5.6, 12.7, 14.5, 19.3 and 20.2 degrees two-theta + 0.2 degrees two-theta.
  • Desonide 21-isobutyrate (70 g, 144 mmol) were added in portions at about -20 0 C to 73% hydrofluoric acid (350 g), and to the resulting solution was added, during ca. 5 minutes, 18.4 grams (164 mmol) of cyclohexanecarboxaldehyde.
  • the reaction mixture was held at -10 0 C to -15°C for 1 hour, then at ca. -30 0 C for 2 hours, and then poured into an ice-cold mixture of 26% ammonium hydroxide solution (87.5 grams) and water (2625 grams). The suspension was stirred for 1 hour, then the precipitate was collected at the filter and rinsed with water.
  • the humid precipitate was distributed between 1000 grams of dichloromethane and 1000 grams of water (adjusted to pH 8 with ammonium hydroxide solution).
  • the organic phase was concentrated at atmospheric pressure to an oily residue (crude product) having an R/S epimer ratio of about 90/10 .
  • Example 4b First Crystallization
  • the oil of example 4a was dissolved in 280 grams of acetone at reflux and the solution diluted, whilst maintaining under reflux, with 1400 grams of isooctane and concentrated at atmospheric pressure until the temperature of the suspension reached 90 0 C.
  • the suspension was cooled under agitation to about 70°C during 30 minutes, and the precipitate was collected at the filter and rinsed with isooctane.
  • the crystals were dried at 80 0 C under vacuum to give 64 grams of ciclesonide with an R/S epimer ratio 96.5/3.5.
  • Example 4c Second Crystallization The product of Example 4b was recrystallized in the same manner as disclosed in
  • Example 4b using 96 grams of acetone and 1400 grams of isooctane to give 56.8 grams of ciclesonide with an R/S epimer ratio 98.3/1.7.
  • Example 4d Third Crystallization The product of Example 4c was recrystallized in the same manner as disclosed in
  • Example 4b using 85 grams of acetone and 1400 grams of isooctane to give 50.5 grams of ciclesonide with an R/S epimer ratio 99.3/0.7.
  • Example 4e Fourth Crystallization The product of Example 4d was recrystallized in the same manner as disclosed in
  • Example 4b using 76 grams of acetone and 1400 grams of isooctane to give 45.9 grams of ciclesonide with an R/S epimer ratio 99.75/0.25.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline de ciclésonide caractérisée par un diagramme de diffraction des rayons X ayant des pics à environ 11,0, 14,8, 15,7, 16,5 et 22,8 degrés deux-thêta ± 0,2 degré deux-thêta, ses procédés de préparation et des compositions pharmaceutiques de celle-ci.
EP07763367A 2006-02-08 2007-02-07 Formes cristallines de ciclesonide Withdrawn EP1904514A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77165406P 2006-02-08 2006-02-08
US77384106P 2006-02-15 2006-02-15
PCT/US2007/003405 WO2007092574A2 (fr) 2006-02-08 2007-02-07 Formes cristallines de ciclesonide

Publications (1)

Publication Number Publication Date
EP1904514A2 true EP1904514A2 (fr) 2008-04-02

Family

ID=38330141

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07763367A Withdrawn EP1904514A2 (fr) 2006-02-08 2007-02-07 Formes cristallines de ciclesonide

Country Status (5)

Country Link
EP (1) EP1904514A2 (fr)
JP (1) JP2009526068A (fr)
CA (1) CA2637815A1 (fr)
IL (1) IL193025A0 (fr)
WO (1) WO2007092574A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008062450A2 (fr) * 2006-09-18 2008-05-29 Cadila Healthcare Limited Polymorphes cristallins de ciclésonide
CN106883283B (zh) * 2015-12-15 2021-02-02 天津金耀集团有限公司 环索奈德一水合物及其晶型与制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0745512B2 (ja) * 1986-10-21 1995-05-17 タマ生化学株式会社 オリザノ−ル構成成分の濃縮精製方法
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
JPH07146125A (ja) * 1993-11-26 1995-06-06 Hitachi Zosen Corp 真直度測定装置
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
MY143936A (en) * 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
WO2005025578A1 (fr) * 2003-09-16 2005-03-24 Altana Pharma Ag Utilisation de ciclesonide dans le traitement de maladies respiratoires
JP2005251505A (ja) * 2004-03-03 2005-09-15 Teijirou Azuma プロトン伝導体
WO2007056181A2 (fr) * 2005-11-02 2007-05-18 Sicor, Inc. Procede perfectionne destine a la preparation de ciclesonide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007092574A2 *

Also Published As

Publication number Publication date
IL193025A0 (en) 2009-02-11
CA2637815A1 (fr) 2007-08-16
JP2009526068A (ja) 2009-07-16
WO2007092574A3 (fr) 2007-10-18
WO2007092574A2 (fr) 2007-08-16

Similar Documents

Publication Publication Date Title
JP7145931B2 (ja) 化合物の結晶多形、その製造方法及び用途
JP2020128380A (ja) リファキシミン
JP5535082B2 (ja) ボセンタン、その多形形態及びその塩の合成方法
JP6594917B2 (ja) 所定の粒子径を有する純粋な非多形結晶性胆汁酸の最適合成
US20090298947A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
JP5439168B2 (ja) ロスバスタチン亜鉛塩
NZ575549A (en) Processes for the preparation of ciclesonide and its crystal form
JP2015508090A (ja) 固体形態のダビガトランエテキシレートメシレート及びその調製方法
US8148353B2 (en) Polymorphs of fluticasone furoate and process for preparation thereof
JP5642766B2 (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
JP2013508272A (ja) ブロムフェナクナトリウムの多形体、及び、ブロムフェナクナトリウム多形体の製造方法
WO2007092574A2 (fr) Formes cristallines de ciclesonide
WO2012077134A1 (fr) Méthode de préparation de polymorphes d'aripiprazole
WO2011153221A1 (fr) Formes d'ixabepilone à l'état solide
US20070232578A1 (en) Crystalline forms of ciclesonide
CN116396312A (zh) 一种枸橼酸艾沙佐米的制备方法
WO2017167949A1 (fr) Formes cristallines de bilastine
WO2019127294A1 (fr) Procédé de purification de ticagrelor
US20180016297A1 (en) Crystalline forms of s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl] 6-alpha,9-alpha-difluoro-17-alpha-(furan-2-yl)carbonyloxy-11-beta-hydroxy-16-alpha-methyl-3-oxoandrosta-1,4-diene-17-beta-carbothioate
WO2017118633A1 (fr) Forme cristalline de ticagrelor
US20100152142A1 (en) Crystalline form ii of tigecycline and processes for preparation thereof
CN113980042A (zh) Crisaborole的晶型及其制备方法和用途
JP2023102679A (ja) ブシラミンの結晶形ｉ
CN117242070A (zh) 4h-吡喃-4-酮结构化cyp11a1抑制剂的固体形式
CN112851595A (zh) 普乐沙福晶型d、普乐沙福中间体晶型s及其制备方法与应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070926

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAX Requested extension states of the european patent have changed

Extension state: RS

Extension state: MK

Extension state: HR

Extension state: BA

Extension state: AL

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080424

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ARONHIME, JUDITH

Inventor name: LEVI, SIGALIT

Inventor name: MACDONALD, PETER, LINDSAY

Inventor name: ROSSETTO, PIERLUIGI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ARONHIME, JUDITH

Inventor name: LEVI, SIGALIT

Inventor name: MACDONALD, PETER, LINDSAY

Inventor name: ROSSETTO, PIERLUIGI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100901